No description available.

Le but de ce travail est la mise au point d'une nouvelle voie de synthèse de dérivés de l'acide L-iduronique, une sous-unité saccharidique constitutive des glycosaminoglycanes comme l'héparine. Les substrats de départ utilisés pour cette synthèse sont des dérivés du glucose, un sucre abondant et bon marché. Nous avons étudié, l'inversion de configuration en C-5 permettant de passer d'un dérivé D-gluco à un dérivé L-ido. La première partie de ce travail porte donc sur les différentes étapes conduisant à l'inversion de configuration. La seconde partie est consacrée à l'obtention de divers dérivés d'acide L-iduronique obtenus par la suite de réactions précédemment mises au point, ainsi qu'à une optimisation des rendements de la synthèse mise au point. / The aim of this work is the conception of a new synthetic approach to L-iduronic acid derivatives, a saccharidic sub-unit part of glycosaminoglycans like heparin. The starting materials used for this synthesis are glucose derivatives, a cheap and abundant sugar. The strategy of the synthesis was to obtain an L-ido derivative from a D-gluco one, by performing an inversion of configuration at position 5. The first part of this work deals with the different reactions leading to the inversion of configuration. The second part concerns the way to obtain L-iduronic acid derivatives by the above studied reactions along with synthesis optimisation

There has been increasing interest in the syntheses of carbohydrates due to their profound role in various biological processes and thus their potential in drug development. Various methods have been developed for the preparation of these oligosaccharides from simpler carbohydrate derivatives both chemically and enzymatically but they must be carefully applied to obtain the desired linkages. The main method that has been used to control the regioselectivity of glycosylations is protecting group chemistry. Unfortunately this requires additional steps lengthening the synthesis sequence. Extensive literature has shown the ability for carbohydrate recognition via organoboron methods through selective binding and their ability to undergo regioselective glycosylation through sugar-derived boronate esters. Exploiting these factors and in extension of previous work done in our laboratory on borinic acid- and boronic acid-catalyzed regioselective glycosylations of carbohydrate derivatives, we proposed a target oriented synthesis of a pentassacharide moiety found in four saponins isolated from Spergularia ramosa.

There has been increasing interest in the syntheses of carbohydrates due to their profound role in various biological processes and thus their potential in drug development. Various methods have been developed for the preparation of these oligosaccharides from simpler carbohydrate derivatives both chemically and enzymatically but they must be carefully applied to obtain the desired linkages. The main method that has been used to control the regioselectivity of glycosylations is protecting group chemistry. Unfortunately this requires additional steps lengthening the synthesis sequence. Extensive literature has shown the ability for carbohydrate recognition via organoboron methods through selective binding and their ability to undergo regioselective glycosylation through sugar-derived boronate esters. Exploiting these factors and in extension of previous work done in our laboratory on borinic acid- and boronic acid-catalyzed regioselective glycosylations of carbohydrate derivatives, we proposed a target oriented synthesis of a pentassacharide moiety found in four saponins isolated from Spergularia ramosa.

Les pentasaccharides sont des inhibiteurs indirects du facteur Xa ayant des profils pharmacocinétiques très prédictibles. En raison de la liaison de forte affinité des pentasaccharides à l'antithrombine, cette pharmacocinétique peut être prédite mais aussi transférée à d'autres molécules qui leur sont liées de manière covalente. L'EP42675 combine dans une seule molécule, une antithrombine directe réversible peptidomimétique (analogue de l'α-NAPAP), et un pentasaccharide inhibiteur indirect du facteur Xa antithrombine dépendant (analogue du fondaparinux). L'EP217609 est le dérivé biotinylé de l'EP42675. Son action anticoagulante peut être neutralisée par l'avidine qui se lie avec une grande affinité et spécificité à la fraction biotine de l'EP217609. La première indication cible de l'EP217609 et de son antidote l'avidine est la chirurgie cardiaque nécessitant une circulation extracorporelle. La deuxième indication cible est le traitement des syndromes coronariens aigus nécessitant ou non une intervention coronarienne percutanée. Les études précliniques et cliniques de phase I et phase IIa résumées ici démontrent l'intérêt d'un tel concept de couplage avec un pentasaccharide : absence de dissociation entre les deux entités, faible variabilité intra et interindividuelle des paramètres pharmacocinétiques et pharmacodynamiques, et une neutralisation de l'activité anticoagulante de l'EP21609 quasi complète et sans effet rebond. / Pentasaccharides are indirect inhibitors of factor Xa with highly predictable pharmacokinetic profiles. Because of the high affinity binding of pentasaccharides to antithrombin, this pharmacokinetics can be predicted but also transferred to other molecules covalently bound to them. EP42675 combines in a single molecule, a reversible direct antithrombin (α-NAPAP peptidomimetic analog), and a pentasaccharide similar to fondaparinux with an indirect anti-factor Xa activity. EP217609 is the biotinylated derivative of EP42675 whose anticoagulant activity can be neutralized by avidin which binds with high affinity and specificity to the biotin moiety of EP217609.The first target indication of EP217609 and its antidote avidin is cardiac surgery requiring extracorporeal circulation. The second target indication is the treatment of acute coronary syndromes requiring or not a percutaneous coronary intervention.The preclinical and clinical Phase I and IIa studies summarized here demonstrate the value of such a coupling concept to the pentasaccharide: absence of dissociation between the two entities, low intra- and interindividual variability of the pharmacokinetic and pharmacodynamic parameters, and an almost complete neutralization of the EP217609 anticoagulant activity with no rebound effect.